The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus ahead of a major drug pricing deal with the Trump ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A ...

Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...

Berkshire Hathaway's diversification, culture, and investment philosophy should still make it a great long-term buy, but investors might have to be patient as the company begins delivering outstanding ...

Eli Lilly partners with NVIDIA to build the world’s most powerful AI supercomputer in pharma, accelerating drug discovery and ...

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up ...

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims ...

Eli Lilly's Mounjaro became India's highest-selling drug in October with ₹100 crore sales. The anti-obesity treatment now ...

The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.